Luciana Pizzatti

List of Publications by Year
in descending order

38 papers	828 citations	430874 18 h-index	501196 28 g-index
39 all docs	39 docs citations	39 times ranked	1440 citing authors

#	Article	IF	Citations
1	Proteomic Workflows for High-Quality Quantitative Proteome and Post-Translational Modification Analysis of Clinically Relevant Samples from Formalin-Fixed Paraffin-Embedded Archives. Journal of Proteome Research, 2021, 20, 1027-1039.	3.7	20
2	Investigation of a new oxazolidine derivative in human resistance acute leukemia cells: deciphering its mechanism of action by label-free proteomic. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1153-1166.	3.0	0
3	The human melanoma proteome atlasâ€"Defining the molecular pathology. Clinical and Translational Medicine, 2021, 11, e473.	4.0	14
4	The Human Melanoma Proteome Atlasâ€"Complementing the melanoma transcriptome. Clinical and Translational Medicine, 2021, 11, e451.	4.0	20
5	Polymorphisms at CYP enzymes, NR1I2 and NR1I3 in association with virologic response to antiretroviral therapy in Brazilian HIV-positive individuals. Pharmacogenomics Journal, 2021, , .	2.0	1
6	Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database. Cancers, 2021, 13, 6224.	3.7	4
7	Toxicoproteomics Disclose Pesticides as Downregulators of TNF-Î±, IL-1Î² and Estrogen Receptor Pathways in Breast Cancer Women Chronically Exposed. Frontiers in Oncology, 2020, 10, 1698.	2.8	14
8	Gene doping and genomic science in sports: where are we?. Bioanalysis, 2020, 12, 801-811.	1.5	12
9	Label-Free Proteomics Revealed Oxidative Stress and Inflammation as Factors That Enhance Chemoresistance in Luminal Breast Cancer. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-15.	4.0	25
10	Doping control analysis at the Rio 2016 Olympic and Paralympic Games. Drug Testing and Analysis, 2017, 9, 1658-1672.	2.6	26
11	Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 469-478.	2.3	18
12	Identifying potential markers in Breast Cancer subtypes using plasma label-free proteomics. Journal of Proteomics, 2017, 151, 33-42.	2.4	35
13	Running ahead of doping: analytical advances and challenges faced by modern laboratories ahead of Rio 2016. Bioanalysis, 2016, 8, 1753-1756.	1.5	6
14	Clinical proteomics in cancer: Where we are. Cancer Letters, 2016, 382, 231-239.	7.2	27
15	Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer. Tumor Biology, 2016, 37, 3775-3783.	1.8	10
16	Kaurenoic Acid Possesses Leishmanicidal Activity by Triggering a NLRP12/IL-1Î²/cNOS/NO Pathway. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	34
17	The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Letters, 2015, 357, 186-195.	7.2	22
18	Discovering the infectome of human endothelial cells challenged with Aspergillus fumigatus applying a mass spectrometry label-free approach. Journal of Proteomics, 2014, 97, 126-140.	2.4	20

#	Article	IF	Citations
19	Label-Free Proteomic Analysis of Breast Cancer Molecular Subtypes. Journal of Proteome Research, 2014, 13, 4752-4772.	3.7	34
20	Mechanisms of kidney repair by human mesenchymal stromal cells after ischemia: A comprehensive view using labelâ€free <scp>MS</scp>^E. Proteomics, 2014, 14, 1480-1493.	2.2	9
21	Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle. Current Medicinal Chemistry, 2014, 21, 3211-3226.	2.4	37
22	Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics. Cancer Letters, 2013, 330, 57-66.	7.2	52
23	Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Proliferation, 2013, 46, 10-22.	5.3	93
24	How can Proteomics Reach Cancer Biomarkers?. Current Proteomics, 2013, 10, 136-149.	0.3	12
25	Wnt/Î²-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer, 2012, 12, 303.	2.6	89
26	Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia. Cancer Cell International, 2012, 12, 28.	4.1	22
27	A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line. Proteome Science, 2012, 10, 23.	1.7	18
28	Labelâ€free MS^E proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance. Proteomics, 2012, 12, 2618-2631.	2.2	42
29	SUZ12 is a candidate target of the nonâ€canonical WNT pathway in the progression of chronic myeloid leukemia. Genes Chromosomes and Cancer, 2010, 49, 107-118.	2.8	26
30	Similar proteomic profiles of human mesenchymal stromal cells from different donors. Cytotherapy, 2009, 11, 268-277.	0.7	11
31	RUNX1T1 is overexpressed in imatinib mesylate-resistant cells. Molecular Medicine Reports, 2009, 2, 657-61.	2.4	7
32	SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Molecular Medicine Reports, 2008, 1, 571-4.	2.4	5
33	Otx2 is a putative candidate to activate mice Msx1 gene from distal enhancer. Biochemical and Biophysical Research Communications, 2007, 358, 655-660.	2.1	3
34	Changes in protein expression due to deleterious mutations in the FA/BRCA pathway. Biochemical and Biophysical Research Communications, 2007, 364, 755-760.	2.1	0
35	SMAD 8 binding to mice Msx1 basal promoter is required for transcriptional activation. Biochemical Journal, 2006, 393, 141-150.	3.7	27
36	Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 929-942.	2.3	28

#	Article	IF	Citations
37	SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Molecular Medicine Reports, 0, , .	2.4	5
38	Networks Establishing Hematopoietic Stem Cell Multipotency and Self-Renewal. , 0, , .		0